Patents by Inventor Georgianna Harris

Georgianna Harris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Toxoplasma gondii cylclic GMP dependent protein kinase G as a chemotherapeutic target for antiprotozoal agents
    Patent number: 7718390
    Abstract: Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.
    Type: Grant
    Filed: September 21, 2006
    Date of Patent: May 18, 2010
    Assignee: Merial Limited
    Inventors: Anne Gurnett, Robert Donald, Georgianna Harris, Paul A. Liberator, Dennis Schmatz, Sandra J. Rattray
  • Cyclic GMP dependent protein kinase as a chemotherapeutic target for antiprotozoal agents
    Publication number: 20070009979
    Abstract: Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.
    Type: Application
    Filed: September 21, 2006
    Publication date: January 11, 2007
    Inventors: Anne Gurnett, Robert Donald, Georgianna Harris, Paul Liberator, Dennis Schmatz, Sandra Rattray
  • Cyclic GMP dependent protein kinase as a chemotherapeutic target for antiprotozoal agents
    Patent number: 7125700
    Abstract: Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: October 24, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Anne Gurnett, Robert Donald, Georgianna Harris, Paul A. Liberator, Dennis Schmatz, Sandra J. Rattray
  • Cyclic GMP dependent protien kinase as a chemotherapeutic target for antiprotozoal agents
    Publication number: 20030211552
    Abstract: Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.
    Type: Application
    Filed: January 21, 2003
    Publication date: November 13, 2003
    Inventors: Anne Gurnett, Robert Donald, Georgianna Harris, Paul A. Liberator, Dennis Schmatz, Sandra J. Rattray
  • Polynucleotide encoding eimeria tenella cGMP dependent protein kinase
    Patent number: 6555358
    Abstract: Protozoal cyclic GMP dependent protein kinases have been isolated and cloned. These enzymes may be used in screening assays to identify potential antiprotozoal agents.
    Type: Grant
    Filed: March 8, 2000
    Date of Patent: April 29, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Anne Gurnett, Paul A. Liberator, Robert Donald, Dennis Schmatz, Georgianna Harris, Sandra J. Rattray
  • Treatment of hyperandrogenic conditions
    Patent number: 5932559
    Abstract: The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5.alpha.-reductase enzymes from 3-oxo-4-oxa and 4-thiasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5.alpha.-reductase enzyme, NADPH. The invention further relates to the isolated inhibitor-cofactor complex.
    Type: Grant
    Filed: April 23, 1998
    Date of Patent: August 3, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Herb G. Bull, Georgianna Harris, Robert W. Myers
  • 17-alkyl-7-substituted-4-aza steroid derivatives as 5-.alpha.-reductase inhibitors
    Patent number: 5763361
    Abstract: The novel compounds of the present invention are those of structural formula I: ##STR1## or a pharmaceutically acceptable salt, or stereoisomer thereof, which are inhibitors of 5.alpha.-reductase, particularly 5.alpha.-reductase type 1. The compounds of formula I are useful in the systemic, including oral, or parenteral or topical treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia which includes female and male pattern baldness, female hirsutism, benign prostafic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as in the treatment of prostatitis. Methods of using the compounds of formula I for the treatment of hyperandrogenic conditions such as acne vulgaris, seborrhea, androgenic alopecia, male pattern baldness, female hirsutism, benign prostatic hyperplasia, and the prevention and treatment of prostatic carcinoma, as well as the treatment of prostatitis are provided, as well as pharmaceutical compositions for the compounds of formula I.
    Type: Grant
    Filed: October 21, 1996
    Date of Patent: June 9, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Georgianna Harris, Richard L. Tolman, Soumya P. Sahoo
  • Treatment of hyperandrogenic conditions
    Patent number: 5756480
    Abstract: The invention concerns the treatment of hyperandrogenic conditions in humans by the formation of a novel mechanism-based irreversible inhibitor of human 5.alpha.-reductase enzymes from 3-oxo-4-oxa end 4-thiasteroids having a 1,2-double bond and the pyridine-nucleotide cofactor of the 5.alpha.-reductase enzyme, NADPH. The invention further relates to the isolated inhibitor-cofactor complex.
    Type: Grant
    Filed: October 24, 1996
    Date of Patent: May 26, 1998
    Assignee: Merck & Co., Inc.
    Inventors: Herb G. Bull, Georgianna Harris, Robert W. Myers
  • 7.beta.-substituted-4-aza-5.alpha.-cholestan-3-ones as 5.alpha. reductase inhibitors useful in the prevention and treatment of hyperandrogenetic disorders
    Patent number: 5527807
    Abstract: Described are new 7.beta.-substituted 4-aza-5.alpha.-cholestan-3-ones and related compounds as 5.alpha.-reductase inhibitors.
    Type: Grant
    Filed: November 15, 1994
    Date of Patent: June 18, 1996
    Assignee: Merck & Co., Inc.
    Inventors: Raman K. Bakshi, Gary H. Rasmusson, Richard L. Tolman, Gool F. Patel, Georgianna Harris